PDF(Pubmed)
Abstract：
Merkel cell carcinoma is a rare, aggressive skin cancer that mainly occurs in elderly and immunocompromised patients. Due to the success of immune checkpoint inhibition in MCC, the importance of immunotherapy and vaccines in MCC has increased in recent years. In this article, we aim to present the current progress and perspectives in the development of vaccines for this disease. Here, we summarize and discuss the current literature and ongoing clinical trials investigating vaccines against MCC. We identified 10 articles through a PubMed search investigating a vaccine against MCC. From the international clinical trial database Clinical.Trials.gov, we identified nine studies on vaccines for the management of MCC, of which seven are actively recruiting. Most of the identified studies investigating a vaccine against MCC are preclinical or phase 1/2 trials. The vaccine principles mainly included DNA- and (synthetic) peptide-based vaccines, but RNA-based vaccines, oncolytic viruses, and the combination of vaccines and immunotherapy are also under investigation for the treatment of MCC. Although the management of MCC is changing, when compared to times before the approval of immune checkpoint inhibitors, it will still take some time before the first MCC vaccine is ready for approval.
摘要：
默克尔细胞癌是一种罕见的，侵袭性皮肤癌，主要发生在老年人和免疫功能低下的患者。由于MCC中免疫检查点抑制的成功，近年来，免疫治疗和疫苗在MCC中的重要性日益增加。在这篇文章中,我们旨在介绍该疾病疫苗开发的当前进展和前景。这里,我们总结并讨论了当前的文献和正在进行的针对MCC疫苗的临床试验。我们通过PubMed搜索确定了10篇文章，研究了针对MCC的疫苗。来自国际临床试验数据库临床。Trials.gov,我们确定了九项关于MCC管理疫苗的研究，其中7人正在积极招聘。研究针对MCC的疫苗的大多数已确定的研究是临床前或1/2期试验。疫苗原理主要包括基于DNA和（合成）肽的疫苗，但是基于RNA的疫苗，溶瘤病毒，疫苗和免疫疗法的组合也在研究中用于治疗MCC。尽管MCC的管理正在发生变化，与批准免疫检查点抑制剂之前的时间相比，第一个MCC疫苗准备批准还需要一段时间。
